Product logins

Find logins to all Clarivate products below.


Chronic Pain – Current Treatment – Current Treatment: Physician Insights – Chronic Pain (US)

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the absence of targeted mechanism-based therapies. As a result, it is difficult to achieve adequate analgesia in all patients despite the extensive armamentarium of chronic pain therapies, including the increasing availability of cost-effective generic treatments. The high cost of chronic pain management stemming from a long duration of treatment and the many lines of therapy often required to maintain analgesic effects are exacerbated by the growth of the market due in part to the increasing prevalence of key population segments, including osteoarthritis pain and chronic back pain. Unfortunately, no truly novel analgesic solutions for chronic pain have launched in recent years. Fixed-dose combinations of nonsteroidal anti-inflammatory drugs and abuse-deterrent formulations of opioid analgesics offer incremental advantages in safety and tolerability but struggle to compete against long-generic and firmly entrenched standards of care.

Questions Answered

  • How is chronic pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
  • What factors drive switching between or discontinuation of select analgesics?
  • What impact has the COVID-19 pandemic had on the prescribing of analgesics for chronic pain?
  • What impact has the more-recent launch of Burke’s Consensi (branded celecoxib / amlodipine) had on physician prescribing behavior for chronic pain?

Content Highlights

Geography: United States

Primary research: Survey of 51 U.S. primary care physicians and 51 U.S. pain specialists

Key drugs covered: Hysingla ER, OxyContin, Nucynta ER, Belbuca, Xtampza ER, Consensi, pregabalin, celecoxib, diclofenac topical gel

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Dry Eye – Current Treatment – Current Treatment: Physician Insights – Dry Eye Disease (EU3)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. In Europe, DED has traditionally been managed…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…